

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Epitopix, LLC
USDA Vet Biologics Establishment Number	365
Product Code	2707.02
True Name	Pasteurella Multocida Bacterial Extract
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Vaxxon SRP Pasteurella - No distributor specified
Date of Compilation Summary	January 12, 2021

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

365 2707.02 Page 1 of 4

Study Type	Efficacy					
Pertaining to	Pasteurella multocida					
Study Purpose	To demonstrate effectiveness against <i>Pasteurella multocida</i>					
Study 1 di posc	serotype 1					
Product Administration	Two doses administered at an 3-week interval by subcutaneous					
1 Toduct Administration						
G4 1 4 • 1	injection.					
Study Animals	Twelve week old chickens were randomly assigned to one of two					
	treatments, vaccinates (20 birds) or placebo (20 birds).					
Challenge Description	Twenty chickens in each group were challenged with Pasteurella					
	multocida 14 days following second vaccination.					
Interval observed after	The chicke	ns were	monitored fo	r 14 days a	ifter challe	nge for
challenge	mortality.					
Results	The primar	y outcon	ne was morta	lity as per	9 CFR 113	3.117.
	Summary					
			Survive	d	Died	l
	Placeb	00	4/20 (20	0%)	16/20 (80	1%)
	Vaccin	nates	20/20 (1		0/20 (0	
	7 40011	14105	20/20 (10070)		0/20 (0	, 0)
	Raw Data					
		due to P	asteurella m	ultocida as	confirmed	d by culture
	Placebo	Death	Culture	Vaccinate	Death	Culture
	ID		confirmed	ID		confirmed
	421	Yes	Yes	423 427	No	No
	422 424	Yes Yes	Yes	4//	No	
	424	165				No
	125		Yes	428	No	No
	425 426	Yes	Yes Yes	428 429	No No	No No
	426	Yes Yes	Yes Yes Yes	428 429 430	No	No No No
		Yes	Yes Yes	428 429	No No No	No No
	426 432	Yes Yes Yes	Yes Yes Yes Yes	428 429 430 431	No No No	No No No
	426 432 434 440 444	Yes Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes	428 429 430 431 433 435 436	No No No No No No	No No No No No No
	426 432 434 440 444 445	Yes Yes Yes Yes Yes Yes Yes Yes Yes	Yes	428 429 430 431 433 435 436 437	No No No No No No No	No
	426 432 434 440 444 445 447	Yes	Yes	428 429 430 431 433 435 436 437 438	No N	No N
	426 432 434 440 444 445 447 448	Yes	Yes	428 429 430 431 433 435 436 437 438 439	No N	No N
	426 432 434 440 444 445 447 448 450	Yes	Yes	428 429 430 431 433 435 436 437 438 439 441	No N	No N
	426 432 434 440 444 445 447 448 450 451	Yes	Yes	428 429 430 431 433 435 436 437 438 439 441	No N	No N
	426 432 434 440 444 445 447 448 450 451 452	Yes	Yes	428 429 430 431 433 435 436 437 438 439 441 442	No N	No N
	426 432 434 440 444 445 447 448 450 451 452 454	Yes	Yes	428 429 430 431 433 435 436 437 438 439 441 442 443	No N	No N
	426 432 434 440 444 445 447 448 450 451 452 454 455	Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes No Yes No Yes	Yes	428 429 430 431 433 435 436 437 438 439 441 442 443 449 453	No N	No N
	426 432 434 440 444 445 447 448 450 451 452 454	Yes	Yes	428 429 430 431 433 435 436 437 438 439 441 442 443	No N	No N
	426 432 434 440 444 445 447 448 450 451 452 454 455 456 459 462	Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes No Yes Yes Yes No No Yes Yes Yes Yes	Yes	428 429 430 431 433 435 436 437 438 439 441 442 443 449 453 457 458 460	No N	No N
	426 432 434 440 444 445 447 448 450 451 452 454 455 456 459 462	Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes No Yes Yes Yes No No Yes Yes Yes Yes	Yes	428 429 430 431 433 435 436 437 438 439 441 442 443 449 453 457 458 460	No N	No N
	426 432 434 440 444 445 447 448 450 451 452 454 455 456 459 462	Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes No Yes Yes Yes No No Yes Yes Yes Yes	Yes	428 429 430 431 433 435 436 437 438 439 441 442 443 449 453 457 458 460	No N	No N

365 2707.02 Page 2 of 4

Study Type	Safety					
Pertaining to	ALL					
Study Purpose	To demonstrate safety of the product under field conditions.					
Product	Two doses administered at a 6-9 week interval by a subcutaneous route of					
Administration	injection.					
Study Animals	A total of 115,575 chickens, 12 weeks of age, were enrolled in the study and					
_	housed at commercial egg or layer operations in three geographically					
	distinct regions of the United States.					
Challenge	Not applicable					
Description						
Interval	No challenge. Ch	hickens were o	bserved for ad	verse events a	and mortality for	
observed after	21 days after each	ch of two vacci	nations given (5-9 weeks apa	art.	
challenge	_					
Results	Summary					
	No adverse even	its were observ	ed in any chicl	cens after vac	cination.	
	Mortality rates v	vere higher in o	controls than va	accinates in a	ll regions.	
	Treatment Number of Birds Total Morta				Mortality Rate	
		Tes	ted	Mortality	(%)	
				20.6	2.40	
	Test Vaccine	59,0	033	286	0.48	
	Control house	s 56,	542	354	0.63	
	Mortality by Ro	egion				
	Treatment	Starting	Mortality	Mortality	Mortality	
		Population	post 1 st Vaccination	Post 2 nd Vaccination	on Rate (%)	
İ	¥7 •	32,177	59	29	0.27	
	Vaccine Serial	32,177				
		32,177				

365 2707.02 Page 3 of 4

Region 2:

Treatment	Starting Population	Mortality post 1 st Vaccination	Mortality Post 2 nd Vaccination	Mortality Rate (%)
Vaccine Serial	11,595	31	35	0.57
Control	11,758	28	49	0.65

Region 3:

Treatment	Starting Population	Mortality post 1 st Vaccination	Mortality Post 2 nd Vaccination	Mortality Rate (%)
Vaccine Serial	15,261	45	87	0.86
Control	15,268	59	105	1.07

USDA Approval Date December 2, 2020

365 2707.02 Page 4 of 4